Sangamo Therapeutics, Inc
SGMOQ- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001001233
No open-market purchases or sales by Sangamo Therapeutics, Inc insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $29.0K in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Sangamo Therapeutics, Inc as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 197
- −5 vs. Q1 2021
- Shares held
- 76.2M
- −3.23M (−4.1%) vs. Q1 2021
- Total value
- $912.0M
- −$82.6M (−8.3%) vs. Q1 2021
- New holders
- 18
- 59 more added
- Sold out
- 23
- 74 more reduced
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SGMOQ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 6 | $29.0K |
| Q1 2026 | 112 | $26.0M |
| Q4 2025 | 105 | $26.2M |
| Q3 2025 | 112 | $42.1M |
| Q2 2025 | 114 | $39.6M |
| Q1 2025 | 122 | $34.5M |
| Q4 2024 | 128 | $62.9M |
| Q3 2024 | 103 | $48.6M |
| Q2 2024 | 129 | $31.1M |
| Q1 2024 | 131 | $68.2M |
| Q4 2023 | 130 | $47.2M |
| Q3 2023 | 135 | $61.3M |
| Q2 2023 | 152 | $137.4M |
| Q1 2023 | 180 | $197.6M |
| Q4 2022 | 182 | $326.0M |
| Q3 2022 | 197 | $477.2M |
| Q2 2022 | 188 | $371.1M |
| Q1 2022 | 195 | $459.6M |
| Q4 2021 | 193 | $577.0M |
| Q3 2021 | 193 | $679.3M |
| Q2 2021 | 197 | $912.0M |
| Q1 2021 | 203 | $994.7M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Sangamo Therapeutics, Inc; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| California Public Employees Retirement System | 0 | $0 | 0.00% | −218,698−100.0% | Sold out |
| Mackay Shields LLC | 0 | $0 | 0.00% | −77,049−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −77,714−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −68,776−100.0% | Sold out |
| Seven Eight Capital, LP | 0 | $0 | 0.00% | −33,800−100.0% | Sold out |
| Athanor Capital, LP | 0 | $0 | 0.00% | −36,248−100.0% | Sold out |
| Skandinaviska Enskilda Banken AB (publ) | 0 | $0 | 0.00% | −34,000−100.0% | Sold out |
| Summit Global Investments | 0 | $0 | 0.00% | −29,636−100.0% | Sold out |
| C M Bidwell & Associates Ltd | 0 | $0 | 0.00% | −12,401−100.0% | Sold out |
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −12,129−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −9,925−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −6,754−100.0% | Sold out |
| Parallax Volatility Advisers, L.P. | 0 | $0 | 0.00% | −3,421−100.0% | Sold out |
| Reilly Financial Advisors, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Sowell Financial Services LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| International Assets Investment Management, LLC | 0 | $0 | 0.00% | −750−100.0% | Sold out |
| Capital Analysts, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −316−100.0% | Sold out |
| RMR Wealth Builders | 0 | $0 | 0.00% | −308−100.0% | Sold out |
| Valeo Financial Advisors, LLC | 0 | $0 | 0.00% | −138−100.0% | Sold out |
| E Fund Management Co., Ltd. | – | – | – | – | Not filed |